Skip to main content
Caplight Logo









Pathalys Pharma

Pathalys Pharma

Private
Raleigh, North CarolinaHealthcare & Life Scienceshttps://pathalys.com/

Last Round

Series B

Aug 20, 2024

Est. Valuation

$295M

Total Funding Raised

$255M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Pathalys Pharma is a biopharmaceutical company that develops advanced therapeutics to address unmet needs in the management of end-stage kidney disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalkidney diseasesecondary hyperparathyroidismSHPThemodialysiscalcimimeticclinical trialsdrug developmentnephrologybiotechclinical-stage pharmaintravenous therapydialysis treatmenttherapeutic asset

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Pathalys Pharma Comparables

Compare Pathalys Pharma with similar companies based on industry and business-model similarity.

Pathalys Pharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Kissei Pharmaceutical
79%
Amgen
77%
Eisai
76%

Pathalys Pharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BAug 20, 2024
Early FundingJan 18, 2023
SeedMar 1, 2022

Key People

Founding team and executive leadership

Neal Fowler

Chief Executive Officer

Executive Team

Pathalys Pharma Investors

Notable investors and investment history

Pathalys Pharma investors
InvestorRounds
Japan Post Investment CorporationSeries B
TCG CrossoverSeries B
KB InvestmentSeries B
KB InvestmentSeries B
OrbiMedEarly Funding
Japan Post Bank Asset Management Co., Ltd.Series B
The Carlyle GroupEarly Funding

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 27, 2026

    Monthly visitors grew 424% MoM, from 283 to 1.5K.

  • Aug 20, 2024

    $105M round led by TCG Crossover.

Pathalys Pharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Pathalys Pharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Pathalys Pharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersRaleigh, North Carolina
Employee Range17
Year Founded2021
Last FundingAug 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?